Novel immunotherapy combination shows promise for pediatric medulloblastoma in mice

Written by Louis Gautier, Future Science Group

A recent study has shown combining immunotherapy with tumor necrosis factor (TNF) in medulloblastoma can completely eradicate tumors in mouse models. The team hope to move to clinical trials soon and to study the treatment in other cancer types. A team from Sanford Burnham Prebys Medical Institute (CA, USA) have demonstrated that TNF can significantly increase the effect of immunotherapy treatment in medulloblastoma mouse models. The pediatric cancer currently only sees survival in 25% of patients, with those carrying p53 mutations being particularly vulnerable. The research group aimed to find a viable replacement for medulloblastoma treatment, which currently includes surgery,...

To view this content, please register now for access

It's completely free